Business Description
Opus Genetics Inc
NAICS : 325412
SIC : 2834
ISIN : US67577R1023
Share Class Description:
FRA:R3X1: Ordinary SharesTotal Employee Number:
28Description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 50.05 | |||||
Equity-to-Asset | -0.69 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -7.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -51 | |||||
3-Year Book Growth Rate | -53.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.56 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 66.89 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 7.22 | |||||
9-Day RSI | 18.85 | |||||
14-Day RSI | 27.17 | |||||
3-1 Month Momentum % | -28.22 | |||||
6-1 Month Momentum % | 93.95 | |||||
12-1 Month Momentum % | 249.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.13 | |||||
Quick Ratio | 7.13 | |||||
Cash Ratio | 6.42 | |||||
Days Sales Outstanding | 79.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.6 | |||||
Shareholder Yield % | -11.37 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -359.13 | |||||
Net Margin % | -892.36 | |||||
EBITDA Margin % | -886.66 | |||||
FCF Margin % | -326.12 | |||||
OCF Margin % | -326.12 | |||||
ROA % | -222.79 | |||||
ROIC % | -435.68 | |||||
3-Year ROIIC % | 1683.34 | |||||
ROC (Joel Greenblatt) % | -50047.55 | |||||
ROCE % | -355.92 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.05 | |||||
PS Ratio | 20.12 | |||||
EV-to-EBIT | -1.98 | |||||
EV-to-EBITDA | -1.98 | |||||
EV-to-Forward-EBITDA | 0.01 | |||||
EV-to-Revenue | 17.56 | |||||
EV-to-Forward-Revenue | 9.45 | |||||
EV-to-FCF | -5.4 | |||||
Price-to-GF-Value | 9.03 | |||||
Earnings Yield (Greenblatt) % | -50.51 | |||||
FCF Yield % | -14.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Opus Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 10.289 | ||
| EPS (TTM) (€) | -1.145 | ||
| Beta | 0.8481 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.43 | ||
| Volatility % | 90.55 | ||
| 14-Day RSI | 27.17 | ||
| 14-Day ATR (€) | 0.151312 | ||
| 20-Day SMA (€) | 3.355 | ||
| 12-1 Month Momentum % | 249.14 | ||
| 52-Week Range (€) | 0.886 - 4.84 | ||
| Shares Outstanding (Mil) | 82.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Opus Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Opus Genetics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 26 days | ||
| Guidance call for 2026 | 2026-06-03 08:45 | 3.36 (-2.89%) | ||
| Guidance call for 2026 | 2026-05-19 11:00 | 3.76 (-6.47%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.28 (+0.94%) | ||
| General meeting for 2026 | 2026-04-20 16:00 | 4.82 (+0.42%) | ||
| RBC Capital Markets Global Ophthalmology Conference | 2026-03-25 11:45 | 3.85 (-1.91%) | ||
| Annual report for 2025 | 2026-03-12 | 4.28 (+3.26%) | ||
| Citizens Life Sciences Conference | 2026-03-11 14:50 | 4.14 (+1.60%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 15:00 | 4.07 (-0.25%) |
Show
Entries
Opus Genetics Inc Frequently Asked Questions
What is Opus Genetics Inc(FRA:R3X1)'s stock price today?
The current price of FRA:R3X1 is €2.80. The 52 week high of FRA:R3X1 is €4.84 and 52 week low is €0.89.
When is next earnings date of Opus Genetics Inc(FRA:R3X1)?
The next earnings date of Opus Genetics Inc(FRA:R3X1) is 2026-08-13 Est..
Does Opus Genetics Inc(FRA:R3X1) pay dividends? If so, how much?
Opus Genetics Inc(FRA:R3X1) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders | 2024-10-23 |
Articles on Opus Genetics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers